Discover open access scientific publications

Search, annotate, share and cite publications

Publications by A. Sumbul

Nivolumab Plus Doxorubicin, Vinblastine and Dacarbazine for Newly Diagnosed Advanced-Stage Classical Hodgkin Lymphoma: Checkmate 205 Cohort D 2-Year Follow-Up

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Nivolumab for Relapsed/Refractory Classical Hodgkin Lymphoma After Autologous Transplant: Full Results After Extended Follow-Up of the Phase 2 Checkmate 205 Trial

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Related publications

Long-Term Follow Up of Patients With Human Immunodeficiency Virus Infection and Advanced Stage Hodgkin's Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine and Dacarbazine

Haematologica
Hematology
2013English

A Pilot Trial of Adriamycin, Pembrolizumab, Vinblastine and Dacarbazine (Apvd) for Patients With Untreated Classical Hodgkin Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

P1.01-02 Long-Term Outcomes With First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 3-Year Follow-Up From CheckMate 012

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Rituximab Plus ABVD in Newly Diagnosed Nodular Lymphocyte-Predominant Hodgkin Lymphoma

British Journal of Haematology
Hematology
2016English

Prognostic Implication of the Absolute Lymphocyte to Absolute Monocyte Count Ratio in Patients With Classical Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine or Equivalent Regimens

Oncologist
Cancer ResearchMedicineOncology
2016English

HIV Status Does Not Influence Outcome in Patients With Classical Hodgkin Lymphoma Treated With Chemotherapy Using Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine in the Highly Active Antiretroviral Therapy Era

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2012English

Response-Adapted Treatment With Nivolumab and Brentuximab Vedotin in Young Patients With Relapsed/Refractory Classical Hodgkin Lymphoma: Checkmate 744 Subgroup Analyses

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

20-Year Follow-Up of Hodgkin Lymphoma: Predictors of Survival and Secondary Malignancies

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy